Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle.

Bartelink IH, Jones EF, Shahidi-Latham SK, Rong ELP, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber G, Wimana Z, Gebhart G.

Clin Pharmacol Ther. 2018 Aug 14. doi: 10.1002/cpt.1211. [Epub ahead of print] Review.

PMID:
30107040
2.

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.

Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, Krajinovic M.

Oncotarget. 2017 Aug 27;8(53):90852-90867. doi: 10.18632/oncotarget.20310. eCollection 2017 Oct 31.

3.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

4.

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN.

Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985.

PMID:
28790114
5.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

6.

Busulfan after HSCT in children and young adults - Authors' reply.

Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ.

Lancet Haematol. 2017 Mar;4(3):e103-e104. doi: 10.1016/S2352-3026(17)30018-2. No abstract available.

PMID:
28257750
7.

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.

Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ.

Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13.

8.

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F.

Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.

9.

Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA.

Clin Pharmacokinet. 2015 Apr;54(4):435-46. doi: 10.1007/s40262-014-0214-6.

PMID:
25466602
10.

Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.

Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):277-86. doi: 10.1097/QAI.0000000000000300.

PMID:
25140906
11.

Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.

Bartelink IH, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, Lindemans CA, Bierings MB, Boelens JJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):345-53. doi: 10.1016/j.bbmt.2013.11.027. Epub 2013 Dec 4.

12.

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F.

J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.

13.

Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.

Trame MN, Bartelink IH, Boos J, Boelens JJ, Hempel G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1149-55. doi: 10.1007/s00280-013-2284-9. Epub 2013 Sep 15.

PMID:
24036908
14.

Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1608-14. doi: 10.1016/j.bbmt.2013.08.014. Epub 2013 Sep 9.

15.

Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M.

Antimicrob Agents Chemother. 2013 Jan;57(1):235-40. doi: 10.1128/AAC.01540-12. Epub 2012 Oct 31.

16.

Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children.

Bartelink IH, Belitser SV, Knibbe CA, Danhof M, de Pagter AJ, Egberts TC, Boelens JJ.

Biol Blood Marrow Transplant. 2013 Feb;19(2):305-13. doi: 10.1016/j.bbmt.2012.10.010. Epub 2012 Oct 22.

17.

Predictive performance of a busulfan pharmacokinetic model in children and young adults.

Bartelink IH, van Kesteren C, Boelens JJ, Egberts TC, Bierings MB, Cuvelier GD, Wynn RF, Slatter MA, Chiesa R, Danhof M, Knibbe CA.

Ther Drug Monit. 2012 Oct;34(5):574-83.

PMID:
22972539
18.

Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.

Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel G, Zwaveling J, Danhof M, Knibbe CA.

Clin Pharmacokinet. 2012 May 1;51(5):331-45. doi: 10.2165/11598180-000000000-00000.

PMID:
22455797
19.

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic Acid: four case reports from the Netherlands and a case/non-case analysis of vigibase.

Beers E, van Puijenbroek EP, Bartelink IH, van der Linden CM, Jansen PA.

Drug Saf. 2010 Jan 1;33(1):47-55. doi: 10.2165/11318950-000000000-00000.

PMID:
20000866
20.

Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs.

Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W.

Dig Dis Sci. 2010 Mar;55(3):716-23. doi: 10.1007/s10620-009-0765-9. Epub 2009 Mar 3.

PMID:
19255843
21.

Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.

Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, Egeler M, Lankester AC, Egberts AC, Zwaveling J, Boelens JJ.

Biol Blood Marrow Transplant. 2009 Feb;15(2):231-41. doi: 10.1016/j.bbmt.2008.11.022.

22.

Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.

Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ.

Ther Drug Monit. 2008 Aug;30(4):504-10. doi: 10.1097/FTD.0b013e3181817428.

PMID:
18641537
23.

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.

Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98.

24.

Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN.

Clin Pharmacokinet. 2006;45(11):1077-97. Review.

PMID:
17048973

Supplemental Content

Loading ...
Support Center